Source:  The Medical Republic – 29 September 2016

Global agricultural giant Monsanto has signed a licensing deal with the Broad Institute of MIT and Harvard to use CRISPR-Cas genome-editing technology to help develop new seeds and crop improvements. CRISPR is a technology used to edit DNA by snipping specific parts of the genetic code so as to modify the characteristics of an organism. For Monsanto, this means being able to integrate specific genes into a plant’s seeds as well as enhancing beneficial, or removing undesirable, plant characteristics so that plant breeders can deliver better hybrids and varieties more efficiently.